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Background: Cerebrovascular complications involving endothelial dysfunction at the blood-brain barrier (BBB) are
central to the pathogenesis of diabetes-related CNS disorders. However, clinical and experimental studies have
reported contrasting evidence in relation to the effects of hyperglycemia on BBB permeability and function. Similarly
the effect of hypoglycemia on BBB integrity is not well understood. Therefore, we assessed the differential impact
of hypo and hyperglycemic conditions on BBB integrity and endothelial function in vitro using hCMEC/D3, a well
characterized human brain microvascular endothelial cell line.
Methods: Parallel monolayers of hCMEC/D3 were exposed to normal, hypo- or hyperglycemic media, containing
5.5, 2.2 or 35 mM D-glucose, respectively. Following 3-24h exposure, the expression and distribution of BBB tight
junction (ZO-1 and claudin-5) adherence junction (VE-cadherin) proteins, and glucose transporters as well as
inflammatory (VCAM-1) and oxidative stress (Nrf-2) markers were analyzed by immunofluorescence and western
blotting. Endothelial release of growth factors and pro-inflammatory cytokines were determined by ELISA. Further,
the impact of altered glycemia on BBB permeability was assessed in hCMEC/D3 – astrocyte co-cultures on Transwell
supports using fluorescent dextrans (4–70 kDa).
Results: Compared to controls, exposure to hypoglycemia (3 and 24h) down-regulated the expression of claudin-5
and disrupted the ZO-1 localization at cell-cell contacts, while hyperglycemia marginally reduced claudin-5 expression
without affecting ZO-1 distribution. Permeability to dextrans (4-10 kDa) and VEGF release at 24h were significantly
increased by hypo- and hyperglycemia, although 70 kDa dextran permeability was increased only under hypoglycemic
conditions. The expression of SGLT-1 was up-regulated at 24h hypoglycemic exposure while only a modest increase of
GLUT-1 expression was observed. In addition, the expression of Nrf-2 and release of interleukin-6 and PDGF-BB, were
down-regulated by hypoglycemia (but not hyperglycemia), while both conditions induced a marginal and transient
increase in VCAM-1 expression from 3 to 24h, including a significant increase in VE-cadherin expression at 3 h
following hyperglycemia.
Conclusions: In summary, our findings demonstrate a potential impairment of BBB integrity and function by hypo or
hyperglycemia, through altered expression/distribution of TJ proteins and nutrient transporters. In addition,
hypoglycemic exposure severely affects the expression of oxidative and inflammatory stress markers of BBB
endothelium.
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The blood-brain barrier (BBB), a dynamic interface be-
tween systemic circulation and brain, precisely regulates
the CNS microenvironment [1]. The BBB selectively re-
stricts blood-borne and xenobiotic entities from entering
the CNS, thus maintaining cerebral homeostasis. These
restrictive properties are bestowed upon the BBB by
unique features of the microcapillary endothelium such
as: 1) expression and organization of intercellular tight
junction (TJ) complexes [2,3]; 2) polarized expression of
specialized carrier systems for selective transport of essen-
tial nutrients; 3) non-selective drug efflux pumps [4,5].
Thus, BBB integrity is critical to ensure optimal CNS
function and its disruption during cerebrovascular path-
ologies can be prodromal to the onset and progression of
major neurological disorders [6].
Increasing evidence indicts BBB dysfunction as a major
cerebrovascular complication in diabetes mellitus that un-
derlies the pathogenesis of a host of CNS disorders [7,8].
Both hypoglycemia and diabetes-dependent chronic hyper-
glycemia have profound impact on cerebrovasculature in
terms of endothelial dysfunction, increased vascular perme-
ability, and altered gene expression, thus leading to poten-
tial neuronal injuries. Chronic hyperglycemia has been
shown to affect BBB permeability, although conflicting evi-
dence exists between animal [9,10] and human studies
[11,12]. Similarly, disparate evidence from clinical and ex-
perimental studies has been reported in relation to the ef-
fects of hyperglycemia on BBB glucose transporters (mainly
GLUT-1) expression and nutrient transport. While some
studies have shown long-standing hyperglycemia being pro-
dromal to a decreased GLUT-1 expression, others have re-
ported an unaltered cerebral glucose metabolism and no
changes in the expression of glucose transporter under
similar conditions. Chronic hypoglycemia has been shown
to elicit BBB over-expression of GLUT-1 perhaps to com-
pensate for low circulating blood glucose levels [13]. How-
ever, the issue of whether altered glycemic conditions may
impact other BBB glucose transporters has only been
marginally addressed. Potential effects of altered glycemia
on TJ expression/redistribution and endothelial oxidative/
inflammatory responses are other under-investigated areas.
Notably, inter-species variations in the expression of BBB
phenotypic markers further impact the translational signifi-
cance of a large number of such studies [14].
Reliable in vitro models that closely mimic the human
BBB microenvironement are essential to understand the
cellular/molecular basis of brain microvessel endothelial
physiology [15], thus facilitating the identification and
characterization of BBB regulatory mechanisms potentially
impaired in diseased states [16,17]. Recently, an immortal-
ized brain microvascular endothelial cell line, hCMEC/D3,
was derived from isolated human primary BBB ECs by len-
tiviral vector-mediated co-expression of human telomeraseand SV40 T antigen [18]. This stable cell line exhibits ro-
bust proliferation while retaining the morphological and
known biochemical phenotype of differentiated human
BBB ECs over many passages [18,19]. This cell line has
been extensively characterized for its utility as a model of
human BBB for CNS drug delivery and translational neu-
rovascular research focusing on BBB function [16,20-22].
Given the increased public attention to diabetes and its
relevance to the pathogenesis of major CNS disorders (e.g.,
Diabetic neuropathy, Alzheimer’s, Dementia, Stroke, De-
pression, etc.), the objective of this study is to assess and
characterize the independent impact of diabetes-associated
hyper and hypoglycemic conditions on BBB integrity and
endothelial function using hCMEC/D3 cell line.
Methods
Materials and reagents
The antibodies used in this study were obtained from the
following sources: Rabbit anti-ZO-1 (#D7D12) and anti-
VE-cadherin (#D87F2) from Cell Signaling Technology
(Danvers, MA, USA); Rabbit anti-GLUT-1 (#ab15309)
and anti-SGLT-1 (#ab14686) from Abcam (Cambridge,
MA, USA); Rabbit anti-GLUT-4 (#sc-7938) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); Donkey anti-
rabbit (#NA934) and sheep anti-mouse (#NA931) HRP-
linked antibodies from GE Healthcare (Piscataway, NJ,
USA); Mouse anti-Claudin 5 (#35-2500), goat anti-mouse
(#A11001) and anti-rabbit (#A21428) conjugated to Alexa
Fluor® 488 and 555 from Invitrogen (Camarillo, CA,
USA). Sterile culture ware was obtained from Fisher Sci-
entific (Pittsburgh, PA, USA), while other reagents and
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) or Bio-Rad laboratories (Hercules, CA, USA).
Fluorescein isothiocyanate (FITC) and Rhodamine B iso-
thiocyanate (RITC) dextrans were purchased from Sigma-
Aldrich, while Cascade Blue®-dextran was obtained from
Invitrogen (Eugene, OR, USA).
Cell culture
The immortalized hCMEC/D3 cell line was donated by
Dr. Couraud (INSERM, Paris). The hCMEC/D3 cells
(passage 28-32) were seeded on collagen-coated culture
flasks (2.5-3 × 104/cm2) or glass slides (4 × 104/cm2) in
EBM-2 basal medium (Lonza, Walkersville, MD, USA)
supplemented with 5% FBS (Atlanta Biologicals, Lawren-
ceville, GA, USA), chemically defined lipid concentrate
(Life technologies, Carlsbad, CA, USA), growth factors,
antibiotic/antimycotic (1:1) and HEPES (10 mM) and
maintained at 37°C with 5% CO2 exposure. Medium was
changed every 2-3 days until the cells reached conflu-
ence. Monolayer integrity of hCMEC/D3 cells at conflu-
ence was confirmed by the expression of endothelial
cell-specific phenotypic markers at cell-cell junctions, as
previously described [18].
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HCMEC/D3 cells were co-cultured with juxtaposed human
astrocytes (ScienCell Research Laboratories, San Diego,
CA, USA) grown on the abluminal side of semipermeable
Transwell® inserts [16,23]. The Transwell® apparatus allows
for the BBB endothelium to remain in anatomical contact
with astrocytes thus closely mimicking the BBB anatomical
structure [17]. Briefly, Transwell® inserts (clear polyester
membranes with 0.4 μm pore size) were seeded with hu-
man primary astrocytes (HA, passage no. 3-4) on the
abluminal side of the microporous membrane and cultured
in DMEM/F12 media with 10% FBS. After 72 h, hCMEC/
D3 cells were loaded on the apical side and grown in EBM-
2 basal medium containing the supplements mentioned
above. Cells in co-cultures were grown in their respective
media for one week before treatment. Confluence and in-
tegrity were checked by phase contrast microscopy and
trans-endothelial electrical resistance (TEER) measurements.
Treatment
HCMEC/D3 cells in monocultures or co-cultures were
maintained overnight in media containing 1% human
serum with no growth factors (referred as low serum
media). The next day, cells were exposed to fresh low
serum media containing 5.5 mM (normal/control),
2.2 mM (hypoglycemic) or 35 mM (hyperglycemic) D-
glucose for 3-24 h. These concentrations were selected
based on previously published reports in vitro [24,25] and
in vivo [13]. Additional osmotic control experiments were
performed by exposing hCMEC/D3 cells to media contain-
ing 5.5 mM D-glucose + 4.5 mM L-glucose, 2.2 mM D-
glucose + 7.8 mM L-glucose or 30 mM D-mannitol. Note
that this mannitol concentration was significantly lower
than the 1.4 M used for transient opening of BBB [26].
Cell viability
Following exposure to normal, hypo or hyperglycemic
(5.5, 2.2 or 35 mM D-glucose respectively) media for 3
and 24 h, cell viability was determined by lactate dehydro-
genase (LDH) measurements in the culture medium by a
colorimetric enzymatic reaction (Pierce LDH cytotoxicity
assay kit - Thermo Scientific, Rockford, IL), according to
the manufacturer guidelines.
BBB integrity
Acute effects of altered glycemia on BBB integrity were
assessed by measuring concomitant paracellular perme-
ability (luminal to abluminal) to labeled dextrans (4-
70 kDa) and TEER (Ω.cm2) measurement by EVOM 2
(World Precision Instruments, Sarasota, FL, USA), as de-
scribed earlier [16,23]. For paracellular permeability stud-
ies, hCMEC/D3 cell monolayers seeded on Transwell
inserts were exposed to normal, hyper or hypoglycemic
media for 30 min at 37°C in humidified incubator prior tothe addition of a mixture of labeled dextrans in PBS
(FITC- 4 kDa, 7 mg/ml; Cascade Blue®- 10 kDa, 5 mg/ml;
and RITC - 70 kDa, 7 mg/ml) to the luminal compart-
ment. Abluminal samples (50 μL) were collected over
60 min and replaced with equal volume of fresh media to
allow sink conditions. Dextran flux was determined by
fluorescent measurements at appropriate excitation and
emission wavelengths for each fluorescent dye. Media-
only samples with no added dextrans and cell-free inserts
with added dextrans served as reference. Similarly, follow-
ing 24 h treatment, TEER values were measured across
hCMEC/D3 cell monolayers. Cell-free inserts were used
to calculate the final resistance.
ELISA
Following treatment, the respective conditioned media from
either mono or co-cultures of hCMEC/D3 cells were ana-
lyzed by Quantikine ELISA kits (R&D systems, Minneapolis,
MN, USA) for vascular endothelial growth factor (VEGF),
platelet derived growth factor (PDGF-BB) and interleukin-6
(IL-6) according to the manufacturer’s protocol.
Immunofluorescence
HCMEC/D3 cells cultured on chamber slides were rinsed
in PBS and fixed with ice-cold acetone (10 min at -20°C).
After PBS washes, fixed cells were blocked with 5% goat
serum in PBS at room temperature (RT) for 30 min,
followed by incubation with rabbit (1:200) or mouse (1:150)
primary antibodies overnight at 4°C. After 3 rinses with
PBS, cells were incubated for 1 h at RT with Alexa Fluor®
488 or 555 conjugated goat anti-mouse or anti-rabbit anti-
bodies, respectively (1:1000). Thereafter, cells were rinsed
and counterstained with DAPI in Prolonged Gold Anti-
fade reagent (Invitrogen, OR, USA). Slides were cover
slipped, cured overnight in dark and examined with EVOS
digital inverted fluorescence microscope. Cell staining de-
void of primary antibodies served as negative controls.
Western blotting
Briefly, cells were lysed in ice-cold RIPA buffer contain-
ing Complete Protease Inhibitor (Roche Diagnostics, In-
dianapolis, IN, USA) and centrifuged at 14000 rpm, 4°C
for 30 min. Protein concentration was determined by
bicinchoninic acid assay [27]. Denatured samples con-
taining equal amounts of protein (12 or 15 μg) were sub-
jected to SDS-PAGE (7.5 or 10%) and electrotransferred
to PVDF or nitrocellulose membranes. Membranes were
blocked for 2 h (RT) with 5% non-fat dry milk in TBS
containing 0.1% Tween-20 (TTBS) and subsequently in-
cubated with rabbit (1:500) or mouse (1:350) primary
antibodies. After 3 washes (10 min each) with TTBS,
membranes were incubated with anti-rabbit or anti-
mouse (1:7000) HRP-conjugated secondary antibodies
(2 h, RT) and washed with TTBS. Bands were detected
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Prime with ChemiDoc™ XRS system. Membranes were
subsequently stripped and probed for β-tubulin (1:500),
as a loading control. Band densities were analyzed by
Quantity One Software.
Statistical analyses
Data from all experiments were expressed as mean ±
standard error of mean (S.E.M) and analyzed by one or
two-way ANOVA using GraphPad Prism Software Inc.
(La Jolla, CA, USA). Post hoc multiple comparison tests
were performed with Tukey’s or Dunnett’s test. P value
less than 0.05 was considered statistically significant.
Results
Effects of altered glycemia on hCMEC/D3 cell viability
LDH release from the damaged cells (a measure of cyto-
toxicity) was determined to assess hCMEC/D3 cell viabil-
ity at 3 and 24 h following exposure to normal, hyper and
hypoglycemic media. Analysis of the results (one-way
ANOVA) clearly indicate a lack of cytotoxic effect of ei-
ther hypo or hyperglycemia on hCMEC/D3 under the
tested exposure conditions (3 and 24 h - see Figure 1A) al-
though hypoglycemia did induce slight (not significant) in-
crease in LDH release at both time points when compared
to controls. These data were also supported by phase con-
trast microscopy analysis of hCMEC/D3 cell cultures (see
Figure 1B) showing complete and fully confluent cell
monolayers devoid of morphological alterations and/or
empty spots indicative of cell injury and death.
Effects of hypo- and hyperglycemia on BBB TJ protein
expression
Side-by-side comparisons of the immunofluorescence
data indicate a predominant and precise distribution of
membrane-associated ZO-1 along the cell-cell junctions,
under normal glycemic conditions at 3 h (Figure 2A) and
24 h (Figure 2B). Exposure to hypoglycemic medium re-
sulted in a significant disruption of the ZO-1 bands at
cell-cell contacts and loss of cell junctions at 3 (Figure 2A)
and 24 h (Figure 2B). This was paralleled by a significant
increase in cytosolic ZO-1 expression, as supported by the
western blots at 3 and 24 h (Figure 2). Hypoglycemic ex-
posure also led to significant and sustained down-
regulation of claudin-5 expression at 3 (Figure 2A) and
24 h (Figure 2B) in hCMEC/D3 cells, as demonstrated by
western blots (Figure 2, p < 0.001; vs. control). In contrast
to hypoglycemia, hyperglycemic exposure for 24 h did not
affect the ZO-1 overall expression (Figure 2B), although
disruption of ZO-1 band at cell-cell contacts (see white ar-
rows) and a slight increase in total ZO-1 expression was
observed following the initial 3 h treatment, compared to
control (Figure 2A). In addition, hyperglycemia did not
affect claudin-5 expression in hCMEC/D3 cell monolayersat either 3 or 24 h, as assessed by western blots (Figure 2),
though a decreased level of expression (albeit not signifi-
cant) was noted at 24 h exposure; Figure 2B). Importantly,
these relative changes in the membrane distribution/ex-
pression of ZO-1 and claudin-5 were not related to the os-
motic effects of low or high D-glucose containing media,
as determined by parallel osmotic control experiments
(data not shown).
Effects of hypo- and hyperglycemia on BBB integrity
VEGF, a potent mediator of vascular permeability, is known
to alter BBB integrity [28]. As shown in Figure 3, one-way
ANOVA revealed a significant effect of treatment on VEGF
release from mono or co-cultures of hCMEC/D3 cells. Spe-
cifically, hypoglycemia induced a significant increase in
VEGF release from hCMEC/D3 cells in monocultures
(two-fold, p < 0.01, Figure 3A) or co-cultured with human
primary astrocytes (> three-fold, p < 0.001, Figure 3B), com-
pared to controls. Similar effect, although less pronounced,
was observed under hyperglycemic conditions resulting in
a significant increase in VEGF release (p < 0.05, Figure 3B).
However, in contrast to hypoglycemia, 24 h of hypergly-
cemia did not affect VEGF release from monocultures of
hCMEC/D3 cells.
On the other hand, TEER values measured across the
hCMEC/D3 monolayers remained relatively stable and
were not affected following an initial 24 h exposure to
hypo or hyperglycemia compared to controls, as shown
in Figure 3C. However, a significant TEER decrease was
observed following 72 h hypoglycemic exposure (vs. con-
trol, p < 0.05). TEER was only moderately decreased by
hyperglycemia over the same time of exposure.
Consistent with VEGF release, BBB permeability to fluor-
escent dextrans was also affected. HCMEC/D3 cells in co-
cultures were exposed to normal, hyper or hypoglycemic
conditions for 30 min at 37°C and then added a mixture
of labeled dextrans (see Methods). Permeability was
measured in acute over 30 min time window following
the addition of dextrans. As shown in Figure 3D, para-
cellular permeability/abluminal accumulation (μg/ml)
of all labeled dextrans (expressed as% controls: 0.195 ±
0.007 × 10-3 cm/min; 0.0975 ± 0.005 × 10-3 cm/min and
0.008 ± 0.0004 × 10-3 cm/min for 4, 10 and 70 kDa re-
spectively) was significantly enhanced by hypoglycemia
over time at 30 min (following the addition of dextrans).
Specifically, the permeability to 4- and 10 kDa dextrans
increased within 15 min (data not shown) and was sig-
nificant at 30 min (p < 0.01 or p < 0.05 vs. control),
while the paracellular flux of 70 kDa dextran reached
statistical significance only at 30 min following the
addition of dextrans to the lumenal side (p < 0.001, vs.
control). These results strongly suggest that even short
exposure to severe hypoglycemic conditions can affect
the integrity and stringency of the BBB. Similarly, acute
Figure 1 Effects of hyper and hypoglycemia on hCMEC/D3 cell viability. (A) LDH release (a measure of cytotoxicity) from the D3 cell
monolayers at 3 and 24 h following exposure to normal, hyper and hypoglycemic conditions. Data were expressed as mean ± S.E.M. (% control). (B)
Phase contrast microscopic images (4×, scale: 1000 μm) of the hCMEC/D3 monolayers following exposure to normal or altered glycemic conditions.
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the permeability of 4- and 10 kDa dextrans (including
70 kDa) by 30 min (p < 0.05, vs. control) following the
addition of dextrans. Importantly, the alteration in BBB in-
tegrity measured by the abluminal accumulation of dex-
trans was not related to the osmotic effects of abnormal
D-glucose concentrations in the media. For example,
hypoglycemic media containing 7.8 mM L-glucose showed
a similar increase in dextran permeability, compared to an
osmotically equivalent normoglycemic medium containing
4.5 mM L-glucose (data not shown).
Hypoglycemia affects expression of glucose transporters
in BBB endothelial cells
Immunofluorescence analysis of hCMEC/D3 cultures
exposed to hypoglycemia for 3 h revealed a significant de-
crease in the expression of GLUT-1 which was corrobo-
rated by western blots as shown in Figure 4A (p < 0.001,
vs. control). Note however, that the effect was transient as
the GLUT-1 expression returned to the levels comparable
or slightly higher than control at 24 h (Figure 4B). No
changes in GLUT-1 expression were noted in culturesexposed to hyperglycemic conditions. By contrast, 24 h
hypoglycemia significantly increased the expression level
of the SGLT-1, a sodium-dependent glucose transporter,
as clearly shown by immunofluorescence analysis of
hCMEC/D3 monolayers and corresponding western blots
(see Figure 4B). However, no significant changes were
observed at 3 h hypoglycemia. Importantly, neither 3 h
nor 24 h hyperglycemia elicited any expression change
of SGLT-1, when compared to controls (Figure 4A & B;
p < 0.01, vs. control). Interestingly, the expression level
of GLUT-4 was up-regulated by hyperglycemia, but
remained unchanged under hypoglycemic culture condi-
tions (Figure 4C; p < 0.05). Importantly, these relative
changes in glucose transporter expression were not related
to the osmotic effects of low or high D-glucose containing
media, as determined by parallel osmotic control experi-
ments mentioned above (data not shown).
Effects of hyper and hypoglycemia on BBB endothelial
cell oxidative and inflammatory stress pathways
Nuclear-factor (erythroid derived 2) related factor-2
(Nrf2) is a potential transcription factor involved in the
Figure 2 Effects of altered glycaemia on expression and distribution of TJ proteins, ZO-1 and claudin-5. Following exposure to control,
hypo or hyperglycemia, hCMEC/D3 cells were dual-labeled for ZO-1 (green) localization by immunofluorescence analysis at 3 h (A) and 24 h (B).
Images were captured at 40× (scale: 100 μm) and merged with DAPI. Immunofluorescence images were paired with corresponding western blot
analyses at 3 and 24 h. Data were expressed as mean ± S.E.M. Representative western blots were shown with β-tubulin as loading control.
*** p < 0.001, ** p < 0.01, * p < 0.05 vs. control. N = 3-4 samples/condition and replicated twice.
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cing the transcription of cytoprotective anti-oxidant genes
[29,30]. Immunofluorescence data indicate a progressivedown-regulation of the cytosolic expression of Nrf-2 in
hCMEC/D3 cells exposed to hypoglycemic culture condi-
tions which became statistically relevant at 24 h. This
Figure 3 Altered glycaemia affects BBB integrity. Hypoglycemia induced a significant increase in extracellular VEGF release from hCMEC/D3
monocultures at 24 h (A). Both, hyper and hypoglycemic exposure significantly up-regulate 24 h VEGF release from hCMEC/D3 cells co-cultured
with astrocytes (B). Hyper and hypoglycemia affect BBB integrity as demonstrated by TEER (ohm.cm2) measurement over 72 h exposure. TEER
values of cell-free inserts served as a reference (C). Also shown in figure were the TEER values during initial set up prior to treatment. Increase
in paracellular permeability of fluorescent dextrans (4-70 kDa) expressed as percentage of control by hyper and hypoglycemia, across the
monolayers of hCMEC/D3 cells (apical or luminal side) co-cultured with astrocytes (abluminal side), at 30 min following the addition of dextrans
(D). Briefly, hCMEC/D3 cells in Transwell inserts were exposed to altered glycemic conditions for 30 min at 37°C, prior to addition of labeled
dextrans. Data were expressed as mean ± S.E.M. *** p < 0.001, ** p < 0.01, * p < 0.05 and # p < 0.05, vs. control. N = 5-6/condition and replicated twice.
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(Figure 5A; p < 0.05 vs control). Further, as shown in
Figure 5B, hypoglycemia significantly decreased the re-
lease of interleukin-6 (IL-6, a pro-inflammatory cytokine
that holds a key role in the inflammatory signaling at BBB
[31]), from hCMEC/D3 monolayers at 3 h (~4-fold de-
crease, p < 0.01, vs. control) and 24 h (~10-fold decrease,
p < 0.01, vs. control). In contrast to hypoglycemia, 24 h
hyperglycemic exposure did not alter total cellular
Nrf-2 expression total or the endothelial release of
IL6, at either 3 or 24 h exposure, as compared to con-
trols (Figure 5B). Release of IL-1β was unaffected by
either conditions (data not shown).As shown in Figure 5C, exposure to hypoglycemic
media significantly decreased the endothelial release of
PDGF-BB at 24 h (p < 0.01, vs. control). Although, slight
decrease in the PDGF-BB release from hCMEC/D3 cells
was noticed following exposure to hyperglycemic condi-
tions, it failed to reach statistical significance (Figure 5C).
Altered glycemia affects the distribution and expression
of VE-cadherin and vascular cell adhesion molecule-1
(VCAM-1) in BBB endothelial cells
As shown in Figure 6, immunofluorescence analyses at 3
and 24 h suggest disruption of membrane-associated VE-
cadherin (an endothelial calcium-dependent adhesion
Figure 4 Effects of hyper and hypoglycemia on the expression and distribution of glucose transporters. Following exposure to control
or altered glycemic conditions, hCMEC/D3 cells were co-stained for immunofluorescence analysis of GLUT-1 (green) and SGLT-1 (red) expression
and distribution at 3 h (A) and 24 h (B). Images were captured at 40× (scale: 100 μm) and merged with DAPI. Results were corroborated by
western blot analyses at 3 and 24 h. Expression of GLUT-4 was assessed by western blot analysis at 24 h following altered glycemia (C). Data were
expressed as mean ± S.E.M. Representative western blots were shown with β-tubulin as loading control. *** p < 0.001, ** p < 0.01, * p < 0.05 and
# p < 0.05, vs. control. N = 3-4 samples/condition and replicated twice.
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BBB integrity [3,19,32]), following hypoglycemic exposure
for 3 and 24 h. This effect was accompanied by a cytosolicredistribution of the protein when compared to controls.
Note that western blots at 3 h exposure did not show
any significant change in total VE-cadherin expression
Figure 5 Effects of altered glycaemia on oxidative stress pathways in BBB endothelial cells. Briefly, hCMEC/D3 cells were exposed to
normal, hyper and hypoglycemic conditions for 3-24 h. (A) The expression and distribution of Nrf-2 (transcription factor involved in the cell’s
anti-oxidative defense) was assessed by immunofluorescence and western blot analysis at 3 and 24 h. Images were captured at 40× (scale:
100 μm) and merged with DAPI. (B) Endothelial release of IL-6 following treatment at 3 and 24 h was quantified by ELISA. Data were
expressed as mean ± S.E.M. (% control). β-tubulin was used as loading control. N = 3-5 samples/condition and replicated twice. Hypoglycemia
down-regulates the endothelial release of PDGF-BB (C).
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(disruption of VE-cadherin at cell-cell contacts) was ob-
served under hyperglycemic condition, although in contrastto hypoglycemia, hyperglycemia significantly increased
total VE-cadherin expression, as demonstrated by western
blots (p < 0.05, vs. control, Figure 6A) at 3 h. However, at
Figure 6 Altered glycaemia-induced increase in BBB endothelial cell inflammation. Following exposure to normal or altered glycemic
conditions for 3 h (A) and 24 h (B), hCMEC/D3 cells were co-stained for the expression and distribution of VE-cadherin (red) and VCAM (green),
important modulators of inflammation. Images were captured at 40× (scale: 100 μm) and merged with DAPI. Representative western blots were
shown with β-tubulin as loading control. Data were expressed as mean ± S.E.M. (% control). N = 3-4 samples/condition and replicated twice.
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sion (Figure 6B) were not observed, thereby suggest-
ing the effect was transient.
In addition to the disruption of VE cadherin, a modest
(not statistically significant) increase of VCAM-1 (both
membrane and soluble fractions) was observed following
3 and 24 h exposure to hypoglycemia (Figure 6A & B).
However, VCAM-1 expression changes observed under
hyperglycemic conditions were transient (Figure 6A & B).
Discussion
In vivo experiments are currently the gold standard in
basic and translational studies; however several factors
generally hinder the utility of animal models to dissect outthe impact of complex pathophysiological stimuli down to
molecular mechanisms. In addition, marked inter-species
differences make it difficult to extrapolate in vivo data to
humans. In this context, development of reliable in vitro
platforms for basic and translational study is supported by
the National Research Council [33]. Recent studies have
shown inter-species variations related to the expression
and distribution of BBB transporters, thus advocating for
the use of humanized models to study in vitro the physio-
logical/pathological responses of the human BBB endothe-
lium in vivo [14,17,34]. Although, various immortalized
endothelial cell lines have been developed, the hCMEC/
D3 cell line stands out as the most well characterized
in vitro human BBB model till date [20]. It has been
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differentiated human BBB endothelium [16,20] over mul-
tiple passages [18,20]. However, the expression of specific
TJ molecules and transporters on hCMEC/D3 cells, though
comparable to primary BMECs [18,35], remained relatively
3-5 fold lower than in isolated human brain microvessels
[36]. Recently, Luissint and colleagues [37] have investi-
gated the molecular partners of claudin-5 and their puta-
tive involvement in regulation and maintenance of BBB TJ
integrity in this cell line. Nevertheless, hCMEC/D3 endo-
thelial cells maintain a restrictive barrier with expression of
functional transporters and intercellular TJs that can be
further enhanced by various stimuli and culture conditions
including exposure to astrocytes and shear stress.
Both claudin-5 and ZO-1 have previously been shown to
play a critical role in BBB TJ formation and organization
[16,38,39]. Our data demonstrate a progressive down-
regulation of claudin-5 expression at cell-cell contacts
following hypoglycemic exposure, while exposure to hyper-
glycemia did not alter its immunoreactivity, in accordance
with previous reports [24]. Surprisingly, an increased
expression of cytosolic ZO-1 was observed at 3 and 24 h
under hypoglycemic conditions. However, prolonged ex-
posure (72 h, data not shown) resulted in significant reduc-
tion of ZO-1, suggesting a time-dependent dysregulation
of ZO-1 at cell-cell contacts by hypoglycemia. It is plaus-
ibly explained that hypoglycemic exposure for 3-24 h
induces a significant translocation of ZO-1 away from
membrane, thus affecting the barrier integrity, as discussed
below. On the other hand, hyperglycemia for 24 h did not
alter ZO-1 expression, as reported earlier [40], although a
significant alteration in its localization (a pronounced cyto-
solic distribution) was observed.
VEGF - an endothelial specific mitogen and a potent
mediator of vascular permeability [28], was shown to
alter BBB integrity in vitro [41] and in vivo [38] by af-
fecting TJ protein expression and organization including
phosphorylation. In addition, our findings are also sup-
ported by previous studies performed in brain [24,41]
and retinal ECs [42]. Notably, our results have shown
significant differences in endothelial response to hypo or
hyperglycemic conditions which manifested through dif-
ferential release of VEGF when ECs were cultured with
or without abluminal astrocytes (Figure 3). Specifically,
VEGF release in response to hypoglycemic media was
significantly enhanced when ECs were co-cultured with
astrocytes as compared to endothelial monocultures.
Interestingly, hyperglycemic exposure showed a two-fold
increase in VEGF release by endothelial cells co-cultured
with astrocytes (Figure 3B), while no significant effects
were observed in monocultures when compared to con-
trols (Figure 3A). However, while no significant TEER
changes were observed within 24 h treatment (despite
the initial increase of VEGF), we observed a significantincrease in permeability to dextran molecules. A statisti-
cally significant TEER decrease was observed only at
72 h which was paralleled by a larger increase in VEGF
release (data not shown) compared to both controls and
24 h exposure (Figure 3C). While we might have ex-
pected a decline in TEER even at 24 h this is not sur-
prising since characteristically relatively low TEER
values commonly obtained (with few exceptions) in
Transwell setups may not provide enough sensitivity to
detect minimal yet significant changes in paracellular
permeability. Such is the case here where relative loss of
BBB integrity was instead demonstrated by changes in
dextran permeability. Nevertheless, hypo and hypergly-
cemia differentially regulate the TJ protein distribution
and expression in a time-dependent manner and thus
negatively affect the BBB integrity and corresponding se-
lective permeability. While the mechanism(s) for the ob-
served effects at this point are still unknown it is
possible that the increase in VEGF expression can be
responsible for these phenomena although other mecha-
nisms (e.g. oxidative/inflammatory stress as mentioned
below) cannot be ruled out and need to be further
investigated.
In line with these findings, our results demonstrate
that hypoglycemia, and hyperglycemia (to some extent),
potentially compromise BBB integrity, as evidenced by a
significant increase in paracellular permeability (abluminal
accumulation) to dextrans in a time-dependent and size-
selective manner in hCMEC/D3 cells co-cultured with as-
trocytes, with a significant increase in permeability to all
labeled dextrans at 60 min following treatment (vs. con-
trols, Figure 3C). These results are supported by a recent
finding in which rapid normalization of plasma glucose in
diabetic rats with acute insulin injection (mimicking acute
hypoglycemia) increased the sucrose permeability at
20 min [43]. Note that similar to sucrose, dextrans cross
the BBB mainly by a paracellular pathway, but not through
cell transcytosis [44]. Moreover, hypoglycemia induced a
similar increase in paracellular flux of all labeled dextrans
at 60 min (data not shown). However, a closer analysis of
permeability at later time points indicates that the para-
cellular fluxes of all dextrans inclined towards steady state
dynamics and therefore, permeability was assessed at
30 min following the addition of dextran markers.
Brain microvascular endothelium is highly enriched
with stereospecific glucose transporters, mainly GLUT-1
(~55 kDa), that selectively facilitate the diffusion of glu-
cose to the CNS [45]. Existing evidence indicates a
decreased GLUT-1 activity and glucose clearance in
chronic hyperglycemia, with a parallel decrease in ex-
pression of GLUT-1 at BBB [46], as confirmed by subse-
quent studies [47,48]. On the other hand, chronic
hypoglycemia increased BBB glucose transport resulting
from a concomitant increase in GLUT-1 transcription
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In line with these observations, we found opposite ef-
fects of hypo and hyperglycemia on GLUT-1 expression
on hCEMC/D3 cells following 3-24 h exposure. Specific-
ally, GLUT-1 expression was progressively up-regulated
by hypoglycemia (24-72 h), following an initial down-
regulation at 3 h. Given the differential regulation of
GLUT-1 expression by hypoglycemia in a time-sensitive
manner, additional studies investigating the effects of
hypoglycemia on glucose transport kinetics would be
important, as GLUT-1 impairment was previously linked
to loss of BBB integrity [50]. Our results also indicate a
marginal decrease in membrane GLUT-1 expression by
prolonged hyperglycemia (slow onset). Interestingly, 24 h
hyperglycemia (but not hypoglycemia) significantly in-
creased the expression of insulin-responsive GLUT-4.
Divergent evidence has been reported on the expression
of this insulin-sensitive glucose transporter across various
brain regions and the cerebral vasculature. However,
GLUT-4 was shown to be expressed in fore brain micro-
vessel endothelium [51], while Ngarmukos and colleagues
reported its expression and co-localization with GLUT-1
and other endothelial marker (such as ZO-1) in brain
glucose-sensing region [52] and could be involved in glu-
cose uptake in hCMEC/D3 cells [53]. Nevertheless, the
functional relevance of this finding is not well under-
stood given the evidence that GLUT-4 expression at
brain microvasculature remains stable during long-
standing diabetes [51].
Importantly, we show for the first time, the differential
regulation of BBB SGLT-1 (~75 kDa isoform) expression
by hypo and hyperglycemia in hCMEC/D3 cells. Data in-
dicate an induction of this sodium-dependent glucose
transporter (2Na+/Glucose) expression specifically by
hypoglycemic exposure from 3-24 h. These findings cor-
roborate previous studies demonstrating an increased
activity of SGLT-1 in bovine brain artery ECs during low
glucose conditions [54], in addition to its role at cere-
brovasculature during oxygen-glucose deprivation [55].
Overall, the present study highlights the concomitant al-
terations in BBB endothelial expression of GLUT-1 and
SGLT-1 under hypoglycemic conditions and further
studies are required to dissect out the relative functional
significance of each transporter.
Existing evidence implicates the potential role of oxi-
dative and inflammatory stress, through overproduction
of reactive oxygen species (ROS), in the development of
various CNS complications in diabetes [56-58]. In fact,
the cerebrovascular endothelium is highly vulnerable to
the oxidative stress resulting in the loss of BBB function
and integrity, via altered composition of the intercellular
TJ complexes as one of the mechanisms [59-61]. Recent
studies have demonstrated the potential role of Nrf-2
in preventing the BBB dysfunction and preserving itsintegrity, by protecting the BBB endothelium from oxi-
dative and inflammatory stress [30,62,63]. Here in, we
demonstrate for the first time a progressive and signifi-
cant loss of Nrf-2 expression by hypoglycemic insult at
24 h suggesting loss of potential protective mechanisms
against oxidative stress thereby leading to increased pro-
duction of ROS as previously reported by others [25]
(Figure 5A), although, it cannot be ruled out that the ob-
served decrease in Nrf-2 can be related to decrease in
cellular metabolism following hypoglycemia. It is logical
to assume that hypoglycemia-induced dysregulation of
TJ proteins is possibly mediated through the down-
regulation of Nrf-2 expression, as Nrf-2 activation was
shown to partially restore TJ proteins and prevent BBB
permeability [63]. In contrast, hyperglycemic exposure
for 24 h did not affect Nrf-2 expression (relative to
control), while previous studies indicate Nrf-2 down-
regulation following chronic hyperglycemic exposure
over 4 days [64].
Interestingly, we observed a significant decline in BBB
endothelial IL-6 release following 3 and 24 h exposure
to hypoglycemic (but not hyperglycemic) conditions
(Figure 5B) which could be attributed to the down-
regulation of Nrf-2. This notion is supported by a recent
finding from Wruck and colleagues [65] that demon-
strates the role of Nrf-2 in regulation of IL-6 gene tran-
scription and suggests a possible role for IL-6 in
oxidative stress defense. Moreover, our data indicate dis-
ruption and relocation of VE-cadherin with a concomi-
tant increase in the soluble VCAM-1 expression, by
hypo and hyperglycemia in hCMEC/D3 cells, effects that
are critical to progression of BBB inflammation and aug-
mented leukocyte infiltration in diabetes [31,59,66,67].
Interestingly, VE-cadherin was shown to positively regu-
late the transcription of claudin-5 [32], thus providing
an alternative explanation for loss of claudin-5 by
hypoglycemia. In addition, hypoglycemic exposure was
shown to down-regulate the PDGF-BB release from
hCMEC/D3 cells (Figure 5C). While the role of PDGF-
BB in BBB physiology and function is emerging, existing
evidence indicates the importance of PDGF-BB/PDGFR-
β signaling for optimal function of pericytes [68], an in-
herent constituent of neurovascular unit that regulates
the BBB function [6]. Taken together, these results sug-
gest that immunological function of BBB is compro-
mised following altered glycaemia and, thus may lead to
subsequent neuroinflammation.
In summary, our in vitro study suggests that hypo and
hyperglycemia differentially impact and potentially impair
BBB integrity and function through altered expression/
distribution of TJ proteins including various glucose
transporters. In addition, hypoglycemic exposure af-
fected the BBB endothelial expression of oxidative and
inflammatory stress markers including VCAM-1 and
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sights into the role and modality of hypoglycemia-
induced BBB dysfunction.
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